NCT03437278 - Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

October 23, 2020

Study Completion Date

February 3, 2021

Conditions

Chronic Spontaneous Urticaria

Interventions

DRUG

Ligelizumab

Ligelizumab comes in 120 mg per 1 ml liquid vials. Participants received one injection every 4 weeks at a dose of 120 mg or 24 mg, high and low doses respectively.

DRUG

Placebo

Placebo 0 mg per 1 ml liquid injection once every 4 weeks.

Trial Locations (20)

1037

Novartis Investigative Site, Budapest

1200

Novartis Investigative Site, Brussels

10002

Novartis Investigative Site, Taipei

13353

Novartis Investigative Site, Berlin

55131

Novartis Investigative Site, Mainz

191015

Novartis Investigative Site, Saint Petersburg

191123

Novartis Investigative Site, Saint Petersburg

214019

Novartis Investigative Site, Smolensk

334001

Novartis Investigative Site, Bikaner

S2000BRH

Novartis Investigative Site, Rosario

B8000JRB

Novartis Investigative Site, Bahía Blanca

C1125ABE

Novartis Investigative Site, Buenos Aires

H3H 1P3

Novartis Investigative Site, Montreal

G1V 4W2

Novartis Investigative Site, Québec

422 101

Novartis Investigative Site, Nashik

110 060

Novartis Investigative Site, New Delhi

08950

Novartis Investigative Site, Esplugues de Llobregat

08006

Novartis Investigative Site, Barcelona

06100

Novartis Investigative Site, Ankara

09100

Novartis Investigative Site, Aydin